Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. We offer highly specialized services within five main disease areas.
Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.
Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.
Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.
AI-assisted NASH histopathology using GHOST
At Gubra, we have developed the deep learning-based app GHOST (Gubra Histopathological Objective Scoring Technology) to automatically perform complete NAFLD Activity Score (NAS) and Fibrosis Staging in liver biopsies with additional quantitative metrics.